GLP-1 agonists effectively reduced weight in adults with congenital heart disease, with an average weight loss of 0.61 kg per month over the full follow-up period.
Cohort (n=27)
No
Does GLP-1 agonist therapy reduce weight in adults with congenital heart disease?
GLP-1 agonists are effective for weight loss in adults with congenital heart disease, with a typical side effect profile, though larger prospective studies are needed.
Mean Difference: -0.61 (95% CI -0.72–-0.5)
p-value: p=<0.0001
BACKGROUND: Glucagon-like-peptide-1 (GLP-1) agonists are beneficial for glycaemic control, weight loss, and cardiovascular health. Because GLP-1 agonists may be a useful tool in the management of obesity in patients with congenital heart disease (CHD), we examined whether GLP-1 agonists are effective and safe for weight loss in adults with congenital heart disease (ACHD) and explored the effects of sex and CHD complexity. METHODS: We conducted a retrospective cohort study of ACHD patients who were prescribed a GLP-1 agonist from 1/1/2022-3/31/2024 at Yale New Haven Hospital. Patients were subdivided by CHD anatomic complexity. The primary outcome was the change in weight over time. Side effects were explored as a secondary outcome. RESULTS: The moderate complexity ACHD group had the fastest weight loss during both the first 6 months and 12 months of treatment, but was comparable to the other two ACHD complexities in the full period of follow-up. Patients in the simple and great complexity groups required 12 months of treatment to reach meaningful weight loss. Females had a faster rate of weight loss compared to males across all ACHD complexity levels. The most common side effects reported were gastrointestinal, such as nausea, acid reflux, and diarrhoea. CONCLUSION: This study provides evidence that GLP-1 agonists are effective for weight loss in ACHD patients, with the greatest weight loss in females and patients with moderate ACHD complexity. Moreover, GLP-1 agonists in the ACHD population have a reasonable side effect profile that is typical for these agents.
Varghese et al. (Mon,) conducted a cohort in Congenital heart disease and obesity or type 2 diabetes (n=27). GLP-1 agonists vs. Baseline weight was evaluated on Monthly average weight loss over the full period of treatment follow-up (-0.61 kg/month, 95% CI -0.72, -0.50, p=<0.0001). GLP-1 agonists effectively reduced weight in adults with congenital heart disease, with an average weight loss of 0.61 kg per month over the full follow-up period.